-
Anticipating new diseases, bioterror methods
The 150 researchers at the University of Florida’s Emerging Pathogens Institute work to anticipate and respond to new diseases and old ones — such as tuberculosis and cholera — that can turn into new threats or make a comeback
-
-
UIC to develop antibiotics against potential bioterrorism agents
The University of Illinois at Chicago receives $4 million in stimulus package funds to develop new antibiotics to treat anthrax, tularemia and plague
-
-
Ricin antidote ready for production
U.K. scientists develop the first antidote to ricin poisoning; security experts say ricin — roughly 1,000 times more toxic than cyanide — could be used in a bio-terror attack; what worries experts about ricin is not only its toxicity, but its ready availability: Ricin is extracted from castor beans, which are processed throughout the world to make castor oil; the toxin is part of the waste “mash” produced when castor oil is made
-
-
NIAID allocated $208 million to fight emerging infectious diseases from bioterrorism
Using its own research funds, augmented by stimulus package money, NIH awarded $208 million to two programs that support research better to understand the human immune response to emerging and re-emerging infectious diseases, including those that may be introduced into a community through acts of bioterrorism
-
-
SRI opens Virginia facility
SRI International opened a new facility for its Center for Advanced Drug Research (CADRE); scientists at the new facility will work on developing vaccines, more quickly diagnosing infections, and developing new treatments
-
-
DHS supports research into Aussie horse and bat disease
Hendra virus infects horses and bats — but the fatality rate among human beings coming into contact with the animals is high because there is no cure for it; the virus and its relative, the Nipah virus, are so lethal that the United States consider them a homeland security threat; there is fear that terrorists may infect bats and then release them near population centers
-
-
-
Kent State to train lab workers for biocontainment
The increasing number of high-containment laboratories and the constant threat from emerging diseases and bioterrorism require more extensive biosafety training of the highest caliber, and more facilities in which to offer this training
-
-
New tool detects -- and neutralizes -- pathogens in mail
Using the mail as a tool for bioterror attacks may or may not kill many people, but it will paralyze a company or an organization; the psychological damage is incalculable; new tool offers mail-room protection
-
-
DARPA seeking to improve bio-threat detectors
The agency is requesting proposals for a device that would enable faster, more accurate detection of a broad range of biological agents; DARPA hopes to create a biosensor that would identify viral and bacterial threats, and do so using a natural first-line of defense: human antibodies
-
-
Kansas officials confident that BioLab project will not be derailed
Congress has allocated $32 million for the design of the Manhattan, Kansas biolab which will replace the aging Plum Island facility; Congress conditioned the release of the rest of the money on the result of studies examining the risks involved in building a biolab in “Tornado alley”; other states that wanted the lab have been slow to give up the fight
-
-
Bipartisan WMD commission: U.S. failing to address urgent biothreat
Interim report assesses progress in preventing WMD proliferation and terrorism
-
-
How prepared is the U.S. for a bioterror attack?
The current U.S. bioterror detection program: A federally funded, locally run program with an $80 million annual budget, deploying a network of vacuum pumps that draw surrounding air through filters, sniffing for signs of biological agents
-
-
U.S. bioterrorism efforts criticized
The task force criticized President Obama for requesting $305 million in 2010 for the Biomedical Advanced Research and Development Authority, which it called “insufficient by a factor of 10”
-
-
Uganda to conduct Marburg and Ebola vaccine trials
Ebola and Marburg are viral infections that have a high mortality, killing 90 percent of victims; no effective treatment exists for these highly infectious diseases, which cause extensive internal bleeding and rapid death
-